The FDA has reportedly halted its controversial fast-track drug review pilot program amid internal turmoil and a prolonged leadership vacuum.
Benzinga
1 story shown
The FDA has reportedly halted its controversial fast-track drug review pilot program amid internal turmoil and a prolonged leadership vacuum.